The present invention aims to provide a method for producing a microneedle device comprising a coating comprising dexmedetomidine and isoproterenol, in which the stability of isoproterenol during production and after production of the microneedle device is high. A method for producing a microneedle device according to one embodiment of the present invention comprises coating microneedles with a coating liquid to form a coating on the microneedles. The microneedle device comprises a substrate, microneedles disposed on the substrate, and a coating formed on the microneedles. The coating liquid comprises dexmedetomidine or a pharmaceutically acceptable salt thereof, isoproterenol or a pharmaceutically acceptable salt thereof, ethylenediaminetetraacetic acid or a pharmaceutically acceptable salt thereof, and a sulfated polysaccharide.

The present invention relates to a catheter device comprising at least one pharmaceutically active compound, wherein the device is capable of releasing said pharmaceutically active compound such as angiogenesis promoting factors, inhibitors of an angiogenesis inhibiting factor or antibiotics over an extended period. It is preferred that the device is tubular and longitudinally extending device assembly with an intraluminal and an extraluminal segment and a proximal and a distal end, wherein the intraluminal segment comprises at least one reversibly expandable portion. Also envisaged is a catheter device for use in preventing a slow-healing or non-healing wound, diabetic foot or intoxication with bacterial toxins, or for treating or preventing bacterial or virus infections and/or medical complications during transplantation.

Provided is a dental pretreatment material for dental tissue regeneration by use of dental pulp stem cells, particularly a dental pretreatment material effectively enabling dental tissue regeneration even by use of dental pulp stem cells of middle-aged or older individuals. The dental pretreatment material is characterized by comprising a serine protease, specifically trypsin. The dental pretreatment material comprising trypsin is used as an injection into a root canal before a root canal filling material comprising dental pulp stem cells and an extracellular matrix is inserted into the root canal as an attempt to regenerate a dental pulp and a dentin. The root canal filling material includes an ALK5 inhibitor, a CCR3 antagonist, or a CCL11 neutralizing antibody.

A non-cellular root canal filler comprises a tetrahydroisoquinoline compound or a pharmaceutically acceptable salt thereof, or a solvate of the compound or the salt, and a dental tissue regeneration promotion kit comprises a pretreatment agent comprising a serine protease, and the non-cellular root canal filler.

A method for treating proliferative diseases by delivering a combination of at least two pharmaceutically active agents to a diseased area or tissue comprising a coating layer of two hydrophobic drugs applied to an exterior surface of a device or a substrate wherein the first pharmaceutically active agent is selected from a group consisting of mTor inhibitors and the second pharmaceutically active agent is selected from a group of consisting of NF-kβ inhibitors. Further a method for treating proliferative diseases by delivering a combination of at least two pharmaceutically active agents to a diseased area or tissue comprising: a coating layer of two hydrophobic drugs applied to an exterior surface of a medical device or substrate and a polymer blend carrier for the pharmaceutically active agents.

The present invention recognizes that medical devices, such as but not limited to contact lenses, can be made having a coating made at least in part using printing technologies to provide drug storage and drug release structures. The coating preferably includes at least one drug reservoir layer and a least one barrier layer, and can include structures, such as but not limited to capillary structures that alone or in combination modulate the release of the drug from the coating. One aspect of the present invention is a medical device that incorporates a drug in at least one coating.

Disclosed are methods, devices and materials for the in situ formation of a nerve cap and/or a nerve wrap to inhibit neuroma formation following planned or traumatic nerve injury. The method includes the steps of identifying a severed end of a nerve, and positioning the severed end into a cavity defined by a form. A transformable media is introduced into the form cavity to surround the severed end. The media is permitted to undergo a transformation from a first, relatively flowable state to a second, relatively non flowable state to form a protective barrier surrounding the severed end. The media may be a hydrogel, and the transformation may produce a synthetic crosslinked hydrogel protective barrier. The media may include at least one anti-regeneration agent to inhibit nerve regrowth

Methods for treating or preventing neointima stenosis are disclosed. The methods generally involve the use of a TGFβ inhibitor, a SMAD2 inhibitor, an FGF Receptor agonist, a Let-7 agonist, or a combination thereof, to inhibit endothelial-to-mesenchymal transition (Endo-MT) of vascular endothelial cells into smooth muscle cells (SMC) at sites of endothelial damage. The disclosed methods can therefore be used to prevent or inhibit neointimal stenosis or restenosis, e.g., after angioplasty, vascular graft, or stent. Also disclosed are methods for increasing the patency of biodegradable, synthetic vascular grafts using a composition that inhibits Endo-MT. A cell-free tissue engineered vascular graft (TEVG) produced by this method is also disclosed.

Compositions, systems, devices, and methods for performing precise chemical treatment of tissues are disclosed. Systems, devices, and methods for administering a chemical agent to one or more a precise regions within a tissue mass are disclosed. Compositions, systems, devices, and methods for treating targeted regions within a tissue mass are disclosed. Systems, devices, and methods for identifying, localizing, monitoring neural traffic in the vicinity of, quantifying neural traffic in the vicinity of, and mapping neural traffic near targeted regions within a tissue mass are disclosed.

The present invention recognizes that medical devices, such as but not limited to contact lenses, can be made having a coating made at least in part using printing technologies to provide drug storage and drug release structures. The coating preferably includes at least one drug reservoir layer and a least one barrier layer, and can include structures, such as but not limited to capillary structures that alone or in combination modulate the release of the drug from the coating. One aspect of the present invention is a medical device that incorporates a drug in at least one coating.